



Company Overview

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

Nov 23 2020, 7:30 AM EST

Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia

Nov 17 2020, 7:30 AM EST

Rigel to Present at the Jefferies Virtual London Healthcare Conference

Nov 10 2020, 7:30 AM EST

Stock Overview

Symbol	RIGL
Exchange	Nasdaq
Market Cap	495.12m
Last Price	\$2.93
52-Week Range	\$1.23 - \$5.24

11/25/2020 04:00 PM EST

Investor Relations

Rigel Pharmaceuticals, Inc.
David Burke
Director, Investor Relations &
Communications
ir@rigel.com

Board of Directors

Gary A. Lyons

Chairman

Raul R. Rodriguez

President and Chief Executive Officer

Bradford S. Goodwin

Director

Keith A. Katkin

Director

Brian Kotzin, M.D.

Director

Gregg Lapointe

Director

Walter H. Moos, Ph.D.

Director

Jane Wasman

Director

Rigel Pharmaceuticals, Inc.

1180 Veterans Blvd
South San Francisco, CA 94080

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.